{"component": "definition", "props": {"groups": [{"size": 11, "snippet_links": [{"key": "development-candidate-criteria", "type": "definition", "offset": [32, 62]}, {"key": "development-program", "type": "clause", "offset": [87, 106]}, {"key": "treatment-of", "type": "definition", "offset": [115, 127]}, {"key": "subject-of", "type": "clause", "offset": [149, 159]}, {"key": "a-notice", "type": "definition", "offset": [160, 168]}, {"key": "development-of-the", "type": "clause", "offset": [241, 259]}, {"key": "in-the-field", "type": "clause", "offset": [269, 281]}, {"key": "section-31", "type": "definition", "offset": [312, 323]}], "samples": [{"hash": "68S373CJgzz", "uri": "/contracts/68S373CJgzz#development-candidate", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.8384666443, "published": true}, {"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#development-candidate", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816562653, "published": true}, {"hash": "aHrGezSDAKR", "uri": "/contracts/aHrGezSDAKR#development-candidate", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7433261871, "published": true}], "snippet": "means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.", "hash": "308b114165aa25554cace4a59b499e0e", "id": 1}, {"size": 9, "snippet_links": [{"key": "collaboration-compound", "type": "definition", "offset": [8, 30]}, {"key": "by-biogen-idec", "type": "clause", "offset": [42, 56]}, {"key": "in-accordance-with", "type": "clause", "offset": [84, 102]}, {"key": "section-26", "type": "clause", "offset": [103, 114]}], "samples": [{"hash": "aiienjUsC7i", "uri": "/contracts/aiienjUsC7i#development-candidate", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 30.1772766113, "published": true}, {"hash": "ib2kw5Wacez", "uri": "/contracts/ib2kw5Wacez#development-candidate", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 25.1752223969, "published": true}, {"hash": "2022DYIeiMZ", "uri": "/contracts/2022DYIeiMZ#development-candidate", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.4921283722, "published": true}], "snippet": "means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.", "hash": "c1f5365e61e3772b4308e2ff102de6ce", "id": 2}, {"size": 9, "snippet_links": [{"key": "antisense-inhibitor", "type": "definition", "offset": [20, 39]}, {"key": "more-specifically", "type": "clause", "offset": [59, 76]}, {"key": "exhibit-a", "type": "clause", "offset": [89, 98]}], "samples": [{"hash": "9VRog5yI0im", "uri": "/contracts/9VRog5yI0im#development-candidate", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "6nkjUkijGZt", "uri": "/contracts/6nkjUkijGZt#development-candidate", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "6KhhfzXliz4", "uri": "https://ir.ionispharma.com/static-files/4d8d833c-c715-4534-8d51-92bd3efa7380", "label": "Amendment", "score": 13.6707735062, "published": false}], "snippet": "means a [...***...] antisense inhibitor of TNF-(alpha), as more specifically detailed in Exhibit A hereto;", "hash": "b7eadd9fe04d7c80ca963214ac5bae4c", "id": 3}, {"size": 9, "snippet_links": [{"key": "section-41", "type": "clause", "offset": [29, 40]}], "samples": [{"hash": "5EwaeM4cXgj", "uri": "/contracts/5EwaeM4cXgj#development-candidate", "label": "Research Collaboration and License Agreement (Atrium Therapeutics, Inc.)", "score": 37.0793991089, "published": true}, {"hash": "kSh6R3UGCXQ", "uri": "/contracts/kSh6R3UGCXQ#development-candidate", "label": "Research Collaboration and License Agreement (Avidity Biosciences, Inc.)", "score": 31.3874053955, "published": true}, {"hash": "bEtBEsr3efo", "uri": "/contracts/bEtBEsr3efo#development-candidate", "label": "Research Collaboration and License Agreement (Avidity Biosciences, Inc.)", "score": 31.2532520294, "published": true}], "snippet": "has the meaning set forth in Section 4.1.", "hash": "f318b55f2747929abdf1bfcd6c5a8a87", "id": 4}, {"size": 8, "snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [21, 37]}, {"key": "therapeutic-agent", "type": "definition", "offset": [80, 97]}, {"key": "treatment-of", "type": "definition", "offset": [106, 118]}, {"key": "based-on", "type": "clause", "offset": [140, 148]}, {"key": "in-vitro", "type": "definition", "offset": [149, 157]}], "samples": [{"hash": "iAP6vBQXNDS", "uri": "/contracts/iAP6vBQXNDS#development-candidate", "label": "License and Collaboration Agreement (Regulus Therapeutics Inc.)", "score": 32.364818573, "published": true}, {"hash": "3qUkQUY5P8p", "uri": "/contracts/3qUkQUY5P8p#development-candidate", "label": "License and Collaboration Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}, {"hash": "f0zJrW1oLsl", "uri": "/contracts/f0zJrW1oLsl#development-candidate", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "means a pre-clinical Licensed Product which possesses desirable properties of a therapeutic agent for the treatment of a clinical condition based on in vitro and animal proof-of-concept studies.", "hash": "d36f7eda12429e9f78fc9abc6fab6de0", "id": 5}, {"size": 8, "snippet_links": [{"key": "development-candidate-criteria", "type": "definition", "offset": [36, 66]}, {"key": "the-jrc", "type": "clause", "offset": [86, 93]}, {"key": "preclinical-development", "type": "clause", "offset": [105, 128]}, {"key": "during-the-research-program-term", "type": "clause", "offset": [129, 161]}, {"key": "washout-period", "type": "definition", "offset": [176, 190]}, {"key": "by-merck", "type": "clause", "offset": [234, 242]}, {"key": "for-development", "type": "clause", "offset": [243, 258]}], "samples": [{"hash": "6wlJ604XC2X", "uri": "/contracts/6wlJ604XC2X#development-candidate", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 23.6830940247, "published": true}, {"hash": "kKte11NmiTM", "uri": "/contracts/kKte11NmiTM#development-candidate", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}, {"hash": "jLuM6apysp9", "uri": "/contracts/jLuM6apysp9#development-candidate", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}], "snippet": "means (1) a Compound that meets the Development Candidate Criteria and is proposed by the JRC for formal preclinical development during the Research Program Term or during the Washout Period; (2) a Deferred Candidate that is selected by Merck for development during the Research Program Term or the Washout Period; or (3) a Compound that has not been proposed to the JRC but is selected by Merck for development.", "hash": "eff28eced63831809b32f96d9278a715", "id": 6}, {"size": 7, "snippet_links": [{"key": "lead-candidate", "type": "definition", "offset": [8, 22]}, {"key": "subject-of", "type": "clause", "offset": [35, 45]}, {"key": "the-fda", "type": "clause", "offset": [64, 71]}, {"key": "in-accordance-with", "type": "clause", "offset": [133, 151]}], "samples": [{"hash": "1PRlwCf6H1w", "uri": "/contracts/1PRlwCf6H1w#development-candidate", "label": "Master Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "jyCPZUGoLnP", "uri": "/contracts/jyCPZUGoLnP#development-candidate", "label": "Master Collaboration Agreement (Prothena Corp PLC)", "score": 29.6242294312, "published": true}, {"hash": "8T8ysQBgaFY", "uri": "/contracts/8T8ysQBgaFY#development-candidate", "label": "Master Collaboration Agreement (Prothena Corp PLC)", "score": 29.3504447937, "published": true}], "snippet": "means a Lead Candidate that is the subject of an IND Filed with the FDA for a Program for which Celgene has exercised its IND Option in accordance with Section 3.1.1.", "hash": "bdc4143c1e24ab3e067cbe82a9e01d2d", "id": 7}, {"size": 7, "snippet_links": [{"key": "single-stranded-rnai-product", "type": "definition", "offset": [8, 36]}], "samples": [{"hash": "9GVrF1AY7bo", "uri": "/contracts/9GVrF1AY7bo#development-candidate", "label": "Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 26.3470230103, "published": true}, {"hash": "2Es5x7ywMXI", "uri": "/contracts/2Es5x7ywMXI#development-candidate", "label": "Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 26.338809967, "published": true}, {"hash": "6qzU6EwFKDo", "uri": "/contracts/6qzU6EwFKDo#development-candidate", "label": "Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet": "means a Single Stranded RNAi Product for which [***] have commenced.", "hash": "e04a4184a9707879eb97512aed21daa1", "id": 8}, {"size": 7, "snippet_links": [{"key": "collaboration-compound", "type": "definition", "offset": [8, 30]}, {"key": "dc-criteria", "type": "definition", "offset": [86, 97]}, {"key": "in-accordance-with", "type": "clause", "offset": [98, 116]}, {"key": "development-candidate-identification", "type": "clause", "offset": [135, 171]}], "samples": [{"hash": "2sDyzVnaJQG", "uri": "/contracts/2sDyzVnaJQG#development-candidate", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.2902107239, "published": true}, {"hash": "ePTlG1r6D3N", "uri": "/contracts/ePTlG1r6D3N#development-candidate", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.0985641479, "published": true}, {"hash": "42jemUzzxtM", "uri": "/contracts/42jemUzzxtM#development-candidate", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 36.0444908142, "published": true}], "snippet": "means a Collaboration Compound that (a) has been determined by the JSC to satisfy the DC Criteria in accordance with Section 3.3.3(a) (Development Candidate Identification), or (b) that the JSC has otherwise designated a Development Candidate in accordance with Section 3.3.3(b) (Development Candidate Identification).", "hash": "0826232d20299853deabb5e876331136", "id": 9}, {"size": 7, "snippet_links": [{"key": "lead-compound", "type": "definition", "offset": [8, 21]}, {"key": "derivative-compound", "type": "definition", "offset": [23, 42]}, {"key": "schering-derivative", "type": "definition", "offset": [46, 65]}, {"key": "therapeutic-agent", "type": "definition", "offset": [112, 129]}, {"key": "treatment-of", "type": "definition", "offset": [152, 164]}], "samples": [{"hash": "kuAPiXMERk0", "uri": "/contracts/kuAPiXMERk0#development-candidate", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "fkc9bftpxIp", "uri": "/contracts/fkc9bftpxIp#development-candidate", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "NLxlZ5c7Pe", "uri": "/contracts/NLxlZ5c7Pe#development-candidate", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet": "means a Lead Compound, Derivative Compound or Schering Derivative which possesses the desirable properties of a therapeutic agent for the prevention or treatment of a clinical condition, in the absence of required safety trials necessary to begin human testing.", "hash": "624d4ab40b6e75f11db7be50fa1f9019", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeZGV2ZWxvcG1lbnQtY2FuZGlkYXRlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 440, "snippet": "means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.", "title": "Development Candidate", "id": "development-candidate", "examples": ["For clarity, \u2587\u2587\u2587\u2587\u2587\u2587\u2019s Final Report for WP3 shall be comprised of [***] relevant for the JSC to evaluate and confirm whether the <strong>Development Candidate</strong> Criteria have been achieved.", "In determining which Lead Generation Candidates should be nominated as <strong>Development Candidates</strong>, the JSC may consider partial fulfillment of certain <strong>Development Candidate</strong> Criteria as being sufficient, provided that substantial progress has been made.", "Within [***], the JSC will evaluate Lead Generation Candidates recommended by the Parties using the applicable <strong>Development Candidate</strong> Criteria to determine which Lead Generation Candidate meet such criteria and should be nominated as <strong>Development Candidates</strong>.", "In addition, \u2587\u2587\u2587\u2587\u2587\u2587\u2019s Final Report for WP3 shall specify the Series for the <strong>Development Candidate</strong>.", "Any such nomination shall still be deemed selection of a <strong>Development Candidate</strong> for purposes of this Agreement, including Section 7.2(b)."], "related": [["product-candidate", "Product Candidate", "Product Candidate"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["lead-compound", "Lead Compound", "Lead Compound"], ["collaboration-target", "Collaboration Target", "Collaboration Target"], ["replacement-candidate", "Replacement Candidate", "Replacement Candidate"]], "related_snippets": [], "updated": "2026-10-15T06:54:30+00:00"}, "json": true, "cursor": ""}}